Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALNY NASDAQ:CVAC NASDAQ:RPRX OTCMKTS:UCBJF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNYAlnylam Pharmaceuticals$303.00+0.6%$318.88$245.96▼$495.55$40.20B0.311.13 million shs1.01 million shsCVACCureVac$4.66$4.66$3.13▼$5.72$1.05B1.77992,546 shsN/ARPRXRoyalty Pharma$50.77+0.6%$47.52$32.15▼$51.65$29.10B0.43.03 million shs3.89 million shsUCBJFUCB$279.96-0.2%$300.47$168.65▼$345.39$52.92B0.47730 shs231 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNYAlnylam Pharmaceuticals+0.63%+0.60%-8.28%-8.53%+12.30%CVACCureVac0.00%0.00%0.00%0.00%+38.69%RPRXRoyalty Pharma+0.64%+2.58%+7.28%+15.11%+58.10%UCBJFUCB-0.17%+2.35%-11.58%-13.31%+85.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNYAlnylam Pharmaceuticals$303.00+0.6%$318.88$245.96▼$495.55$40.20B0.311.13 million shs1.01 million shsCVACCureVac$4.66$4.66$3.13▼$5.72$1.05B1.77992,546 shsN/ARPRXRoyalty Pharma$50.77+0.6%$47.52$32.15▼$51.65$29.10B0.43.03 million shs3.89 million shsUCBJFUCB$279.96-0.2%$300.47$168.65▼$345.39$52.92B0.47730 shs231 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNYAlnylam Pharmaceuticals+0.63%+0.60%-8.28%-8.53%+12.30%CVACCureVac0.00%0.00%0.00%0.00%+38.69%RPRXRoyalty Pharma+0.64%+2.58%+7.28%+15.11%+58.10%UCBJFUCB-0.17%+2.35%-11.58%-13.31%+85.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNYAlnylam Pharmaceuticals 2.81Moderate Buy$471.9655.76% UpsideCVACCureVac 1.80Reduce$6.8346.64% UpsideRPRXRoyalty Pharma 3.00Buy$50.33-0.85% DownsideUCBJFUCB 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest ALNY, RPRX, UCBJF, and CVAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026ALNYAlnylam Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$510.005/4/2026ALNYAlnylam Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/1/2026RPRXRoyalty Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/1/2026ALNYAlnylam Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$450.00 ➝ $445.005/1/2026ALNYAlnylam Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$376.00 ➝ $377.004/21/2026RPRXRoyalty Pharma UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$51.00 ➝ $57.004/13/2026ALNYAlnylam Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$515.00 ➝ $505.004/10/2026RPRXRoyalty Pharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$61.00 ➝ $63.004/6/2026ALNYAlnylam Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)3/25/2026ALNYAlnylam Pharmaceuticals Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$425.003/25/2026ALNYAlnylam Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$510.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNYAlnylam Pharmaceuticals$3.71B10.89$2.81 per share107.69$8.05 per share37.64CVACCureVac$70.74M14.78$0.99 per share4.73$3.36 per share1.39RPRXRoyalty Pharma$2.38B12.31$4.81 per share10.56$16.83 per share3.02UCBJFUCB$5.27B10.05$12.03 per share23.28$50.52 per share5.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNYAlnylam Pharmaceuticals$313.75M$3.6682.7928.37N/A11.72%85.76%10.32%N/ACVACCureVac$175.50M$0.726.47N/AN/A199.92%-23.03%-19.09%N/ARPRXRoyalty Pharma$770.95M$1.3537.609.403.2232.38%28.21%14.55%N/AUCBJFUCB$371.23MN/AN/A39.65N/AN/AN/AN/A7/26/2026 (Estimated)Latest ALNY, RPRX, UCBJF, and CVAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2026Q1 2026ALNYAlnylam Pharmaceuticals$0.8720$1.99+$1.1180$1.51$1.12 billion$1.17 billion2/12/2026Q4 2025ALNYAlnylam Pharmaceuticals$1.43$1.25-$0.18$0.82$1.16 billion$1.10 billion2/11/2026Q4 2025RPRXRoyalty Pharma$1.33$1.46+$0.13$0.50$839.97 million$621.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALNYAlnylam PharmaceuticalsN/AN/AN/AN/AN/ACVACCureVacN/AN/AN/AN/AN/ARPRXRoyalty Pharma$0.941.85%+24.01%69.63%5 YearsUCBJFUCBN/AN/AN/AN/AN/ALatest ALNY, RPRX, UCBJF, and CVAC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/17/2026RPRXRoyalty Pharmaquarterly$0.23501.88%5/15/20265/15/20266/10/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNYAlnylam Pharmaceuticals0.943.133.06CVACCureVac0.033.703.69RPRXRoyalty Pharma0.882.402.40UCBJFUCB0.331.190.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNYAlnylam Pharmaceuticals92.97%CVACCureVac17.26%RPRXRoyalty Pharma54.35%UCBJFUCBN/AInsider OwnershipCompanyInsider OwnershipALNYAlnylam Pharmaceuticals0.86%CVACCureVac2.15%RPRXRoyalty Pharma18.84%UCBJFUCBN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALNYAlnylam Pharmaceuticals2,770133.51 million132.37 millionOptionableCVACCureVac880224.34 million219.52 millionOptionableRPRXRoyalty Pharma80576.86 million468.18 millionOptionableUCBJFUCB9,083189.02 millionN/ANot OptionableALNY, RPRX, UCBJF, and CVAC HeadlinesRecent News About These CompaniesBelgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billionMay 3, 2026 | reuters.comComparing UCB (OTCMKTS:UCBJF) & Evofem Biosciences (NASDAQ:EVFM)May 2, 2026 | americanbankingnews.comUCB (OTCMKTS:UCBJF) Shares Gap Down - Here's WhyApril 29, 2026 | marketbeat.comUCB (OTCMKTS:UCBJF) Shares Gap Up - What's Next?April 23, 2026 | marketbeat.comBelgian pharma UCB to buy U.S.-based Neurona for up to $1.15BApril 17, 2026 | seekingalpha.comUCB (OTCMKTS:UCBJF) Shares Gap Down - Here's What HappenedApril 16, 2026 | marketbeat.comUCB SA (OTCMKTS:UCBJF) Given Consensus Rating of "Buy" by AnalystsApril 14, 2026 | marketbeat.comUCB (OTCMKTS:UCBJF) Shares Down 8.1% - Here's What HappenedApril 9, 2026 | marketbeat.comBelgium's UCB in autoimmune drug deal with AntengeneMarch 3, 2026 | reuters.comDay by Day maintains UCB (UCBJF) buy recommendationDecember 17, 2025 | msn.comUCB price target raised to EUR 300 from EUR 230 at JPMorganDecember 8, 2025 | msn.comUCB removed from European Conviction List at Goldman SachsNovember 4, 2025 | msn.comUCB assumed with an Underperform at JefferiesOctober 27, 2025 | msn.comUCB announces new three-year data from Phase 3 trials on BIMZELXOctober 26, 2025 | msn.comUnited Community Banks, Inc. (UCB) Q3 2025 Earnings Call TranscriptOctober 22, 2025 | seekingalpha.comUCB price target raised to EUR 290 from EUR 220 at BerenbergOctober 14, 2025 | msn.comUCB price target raised to EUR 285 from EUR 250 at Deutsche BankOctober 6, 2025 | msn.comMoonLake rebounds despite downgrades prompted by trial setbackSeptember 30, 2025 | msn.comUCB price target raised to EUR 240 from EUR 220 at Morgan StanleySeptember 8, 2025 | msn.comUCB SA (UCBJF) Q2 2025 Earnings Call TranscriptAugust 1, 2025 | seekingalpha.comUnited Community Banks, Inc. (UCB) Q2 2025 Earnings Call TranscriptJuly 23, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALNY, RPRX, UCBJF, and CVAC Company DescriptionsAlnylam Pharmaceuticals NASDAQ:ALNY$303.00 +1.89 (+0.63%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$303.50 +0.50 (+0.16%) As of 06:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.CureVac NASDAQ:CVAC$4.66 0.00 (0.00%) As of 05/5/2026CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Royalty Pharma NASDAQ:RPRX$50.76 +0.33 (+0.64%) Closing price 05/6/2026 03:59 PM EasternExtended Trading$50.75 -0.01 (-0.03%) As of 06:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.UCB OTCMKTS:UCBJF$279.96 -0.48 (-0.17%) As of 05/6/2026 03:39 PM EasternUCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
